N-[(2S,3R,4R,5R,6R)-2-[(2S,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

Term ID

CHEBI:153465

Synonyms

2-acetamido-2-deoxy-beta-D-galacto-hexopyranosyl-(1->2)-alpha-D-manno-hexopyranosyl-(1->6)-beta-D-gluco-hexopyranose
GalNAc(b1-2)Man(a1-6)b-Glc
WURCS=2.0/3,3,2/[a2122h-1b_1-5][a1122h-1a_1-5][a2112h-1b_1-5_2*NCC/3=O]/1-2-3/a6-b1_b2-c1

Definition

References

GlyTouCan:G70408LU

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from N-[(2S,3R,4R,5R,6R)-2-[(2S,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

Phenotype where environments contain N-[(2S,3R,4R,5R,6R)-2-[(2S,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

Phenotype modified by environments containing N-[(2S,3R,4R,5R,6R)-2-[(2S,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

Phenotype affecting N-[(2S,3R,4R,5R,6R)-2-[(2S,3S,4S,5S,6R)-4,5-Dihydroxy-6-(hydroxymethyl)-2-[[(2R,3S,4S,5R,6R)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]oxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide

Human Disease Model